NCT00939562

Bioequivalence Between Two Tablet Formulations Of Doxycycline Carragenate

An Open-Label, Two-Treatment, Two-Period, Randomized Cross-Over Study To Assess The Bioequivalence Between Commercial Doxycycline Carragenate And Monohydrate Tablet Formulations In Normal Healthy Male Subjects

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Pfizer · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this protocol is to study if two different tablet formulations of doxycycline are bioequivalent to each other.

Conditions

• Bacterial Infection

Interventions

Type	Name	Description
DRUG	doxycycline monohydrate tablet	Tablet, 100 mg, Single dose
DRUG	doxycycline carragenate tablet	Tablet, 100 mg, Single dose

Timeline

• Start date: 2008-11-01
• Primary completion: 2008-12-01
• Completion: 2008-12-01
• First posted: 2009-07-15
• Last updated: 2009-12-23
• Results posted: 2009-12-23

Locations

1 site across 1 country: India